Malaysia’s transition from toxic, 20-month injectable regimens to 6-month all-oral BPaLM therapy has revolutionized drug-resistant tuberculosis management, cutting treatment duration by 70%, reducing drug costs by 80%, and shortening median culture conversion to just 32 days while averting irreversible ototoxicity. Coupled with nationwide decentralized molecular testing and genomic resistance surveillance, this operational framework delivers a proven, patient-centred model for reimagining drug-resistant respiratory care across the Asia-Pacific.